Unlock instant, AI-driven research and patent intelligence for your innovation.

Adenovirus serotype 26 and serotype 35 filovirus vaccines

A filovirus antigen, adenovirus technology, applied in the field of adenovirus vector

Active Publication Date: 2016-05-04
美国卫生和人类服务部 +1
View PDF9 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Ad26 neutralizing antibody titers remain significantly lower than Ad5 neutralizing antibody titers, although seropositivity for Ad26 is highly pronounced in certain adult populations (Abbink, et al., 2007; Mast, et al., 2010)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adenovirus serotype 26 and serotype 35 filovirus vaccines
  • Adenovirus serotype 26 and serotype 35 filovirus vaccines
  • Adenovirus serotype 26 and serotype 35 filovirus vaccines

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0059] The preparation and use of immunogenic compositions are well known to those skilled in the art. Liquid pharmaceutical compositions generally contain a liquid carrier such as water, petroleum, animal or vegetable oil, mineral oil or synthetic oil. It may also contain physiological saline solution, dextrose or other carbohydrate solutions, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol.

[0060] The compositions are suitable for single administration or for serial administration. When administered in series, the first (prime) dose is followed by a vaccination to boost the immune response, often referred to as a booster vaccination. The compositions of the invention can be used as boosting compositions, primed with antigen using a variety of different priming compositions, or as priming compositions. Accordingly, one aspect of the invention provides a method of priming and / or boosting an immune response to an antigen in an individual. For ex...

Embodiment

[0076] The following examples are provided to illustrate, but not limit, the claimed invention

[0077] Depending on the need for immediate or long-term immunity, either a single vaccination or a prime-boost immunization has different advantages that must be taken into account when optimizing the immunization regimen. EBOV and other filoviruses tend to emerge suddenly and spread rapidly among populations with poor medical facilities. Therefore, in these cases, a short vaccine regimen is desirable. For this reason, a single vaccination with the rAd5 vector containing the EBOV glycoprotein (GP) and nucleoprotein (NP) genes has been developed in non-human primates (Sullivan, et al., 2006). These vaccines were shown to elicit a strong immune response within one month (Sullivan, et al., 2003), possibly due to the high level expression of the insert and the tropism of Ad5 for dendritic cells. On the other hand, long-term protective immunity may require a prime-boost vaccine regime...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides recombinant adenoviral vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenoviral vectors can be used to induce a protective immune response against filovirus infection.

Description

technical field [0001] The present invention relates to adenoviral vectors for inducing protective immunity against filovirus infection. Background technique [0002] Replication-defective adenoviral vectors (rAd) are potent inducers of cellular immune responses and thus can be used as useful vectors for genetic vaccines, especially against lentiviruses and filoviruses as well as some other nonviral pathogens (Shiver, et al.,( 2002) Nature415(6869):331-5; (Hill, et al., HumVaccin6(1):78-83.; Sullivan, et al., (2000) Nature408(6812):605-9; Sullivan et al., (2003) Nature424(6949):681-4; Sullivan, et al., (2006) PLoSMed3(6):e177; Radosevic, et al., (2007); Santra, et al., (2009) Vaccine27(42):5837-45) Adenovirus-based vaccines have several advantages as human vaccines because they can be produced to high titers under GMP conditions and they have been shown to be safe and immunogenic in humans (Asmuth, et al. ., JInfectDis201(1):132-41; Kibuuka, et al., JInfectDis201(4):600-7;...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N7/01A61K39/12A61K39/235A61K39/00
CPCA61K39/12A61K2039/5254A61K2039/5256A61K2039/70A61P31/12A61P31/14A61P37/02C12N2710/10034C12N2710/10043C12N2760/14034C12N2760/14134A61K39/235C12N7/00C12N15/861C07K14/005
Inventor N·J·沙利文G·J·纳贝尔C·亚仕都C·程M·G·帕乌J·古迪斯米茨
Owner 美国卫生和人类服务部